Alto Neuroscience, Inc.
ANRONext catalyst
ALTO-300
Major Depressive Disorder
Get an email about ANRO's next catalysts
Track Alto Neuroscience (ANRO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 2 past
ALTO-300 Phase 2 Est. Readout
Estimated primary completion for ALTO-300 trial (NCT05922878) in Major Depressive Disorder. Topline data typically follows completion by weeks to months.
SourceALTO-100 Phase 2 Est. Readout
Estimated primary completion for ALTO-100 trial (NCT06656416) in Bipolar Disorder I or II With a Major Depressive Episode. Topline data typically follows completion by weeks to months.
SourceALTO-207 Phase 2 Est. Readout
Primary completion for ALTO-207 trial (NCT07553637) in Treatment-resistant Depression (TRD)
SourceHow ANRO's past catalysts played out
Market Overview
Stock performance and key metrics
XKH004
Phase III
ALTO-100
Bipolar Disorder I or II With a Major Depressive Episode
ALTO-300 oral (PO) tablet
Major Depressive Disorder
ALTO-100 PO tablet
Major Depressive Disorder
ALTO-300 PO Tablet
Major Depressive Disorder
ALTO-300
Major Depressive Disorder
ALTO-101
Schizophrenia
PA1010
Chronic HBV Infection
PA9159 nasal
Allergic Rhinitis
ALTO-203
Major Depressive Disorder
PA9159 Metered-Dose Inhaler
Bronchial Asthma
GB001 recombinant peptide spray low dose group、high dose group
Healthy
ALTO-207
Treatment-resistant Depression (TRD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
XKH004 | Phase 3 | Phase III | - | - |
ALTO-100 | Phase 2 | Bipolar Disorder I or II With a Major Depressive Episode | - | - |
ALTO-300 oral (PO) tablet | Phase 2 | Major Depressive Disorder | - | - |
ALTO-100 PO tablet | Phase 2 | Major Depressive Disorder | - | - |
ALTO-300 PO Tablet | Phase 2 | Major Depressive Disorder | - | - |
ALTO-300 | Phase 2 | Major Depressive Disorder | - | - |
ALTO-101 | Phase 2 | Schizophrenia | - | - |
PA1010 | Phase 2 | Chronic HBV Infection | - | - |
PA9159 nasal | Phase 2 | Allergic Rhinitis | - | - |
ALTO-203 | Phase 2 | Major Depressive Disorder | - | - |
PA9159 Metered-Dose Inhaler | Phase 2 | Bronchial Asthma | - | - |
GB001 recombinant peptide spray low dose group、high dose group | Phase 2 | Healthy | - | - |
ALTO-207 | Phase 2 | Treatment-resistant Depression (TRD) | - | - |
Diffuse Large B-cell Lymphoma
1 drug in this indication
Major Depressive Disorder
1 drug in this indication
Advanced Solid Tumor
1 drug in this indication
Gastrointestinal Cancer
1 drug in this indication
HCC - Hepatocellular Carcinoma
1 drug in this indication
HER2-positive Breast Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Alto Neuroscience, Inc.'s drug pipeline?→
CatalystAlert tracks 13 drug candidates in Alto Neuroscience, Inc.'s (ANRO) pipeline across Phase 3, Phase 2. Its lead program is XKH004 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alto Neuroscience, Inc.'s next FDA catalyst?→
Alto Neuroscience, Inc.'s (ANRO) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ANRO biotech catalysts?→
Add ANRO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alto Neuroscience, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
